Osteocalcin
To view the entire topic, please log in or purchase a subscription.
Nursing Central is an award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Explore these free sample topics:
-- The first section of this topic is shown below --
Synonym/Acronym:
Bone GLA protein, BGP.
Rationale
To assist in assessment of risk for osteoporosis and to evaluate effectiveness of therapeutic interventions.
Patient Preparation
There are no food, fluid, activity, or medication restrictions unless by medical direction.
Normal Findings
Method: Electrochemiluminescence.
| Age and Sex | Conventional Units | SI Units (Conventional Units × 1) |
|---|---|---|
| 6 mo–6 yr | ||
| Male | 39–121 ng/mL | 39–121 mcg/L |
| Female | 44–130 ng/mL | 44–130 mcg/L |
| 7–9 yr | ||
| Male | 66–182 ng/mL | 66–182 mcg/L |
| Female | 73–206 ng/mL | 73–206 mcg/L |
| 10–12 yr | ||
| Male | 85–232 ng/mL | 85–232 mcg/L |
| Female | 77–262 ng/mL | 77–262 mcg/L |
| 13–15 yr | ||
| Male | 70–336 ng/mL | 70–336 mcg/L |
| Female | 33–222 ng/mL | 33–222 mcg/L |
| 16–17 yr | ||
| Male | 43–237 ng/mL | 43–237 mcg/L |
| Female | 24–99 ng/mL | 24–99 mcg/L |
| Adult | ||
| Male | 3–40 ng/mL | 3–40 mcg/L |
| Female | ||
| Premenopausal | 5–30 ng/mL | 5–30 mcg/L |
| Postmenopausal | 9–50 ng/mL | 9–50 mcg/L |
Critical Findings and Potential Interventions
N/A
-- To view the remaining sections of this topic, please log in or purchase a subscription --
Synonym/Acronym:
Bone GLA protein, BGP.
Rationale
To assist in assessment of risk for osteoporosis and to evaluate effectiveness of therapeutic interventions.
Patient Preparation
There are no food, fluid, activity, or medication restrictions unless by medical direction.
Normal Findings
Method: Electrochemiluminescence.
| Age and Sex | Conventional Units | SI Units (Conventional Units × 1) |
|---|---|---|
| 6 mo–6 yr | ||
| Male | 39–121 ng/mL | 39–121 mcg/L |
| Female | 44–130 ng/mL | 44–130 mcg/L |
| 7–9 yr | ||
| Male | 66–182 ng/mL | 66–182 mcg/L |
| Female | 73–206 ng/mL | 73–206 mcg/L |
| 10–12 yr | ||
| Male | 85–232 ng/mL | 85–232 mcg/L |
| Female | 77–262 ng/mL | 77–262 mcg/L |
| 13–15 yr | ||
| Male | 70–336 ng/mL | 70–336 mcg/L |
| Female | 33–222 ng/mL | 33–222 mcg/L |
| 16–17 yr | ||
| Male | 43–237 ng/mL | 43–237 mcg/L |
| Female | 24–99 ng/mL | 24–99 mcg/L |
| Adult | ||
| Male | 3–40 ng/mL | 3–40 mcg/L |
| Female | ||
| Premenopausal | 5–30 ng/mL | 5–30 mcg/L |
| Postmenopausal | 9–50 ng/mL | 9–50 mcg/L |
Critical Findings and Potential Interventions
N/A
There's more to see -- the rest of this topic is available only to subscribers.